Merck and Daiichi Sankyo Report the Initiation of P-III (IDeate-Lung02) Study of Ifinatamab Deruxtecan to Treat Small Cell Lung Cancer
Shots:
- The companies have dosed the first patient in the P-III (IDeate-Lung02) trial assessing the safety & efficacy of ifinatamab deruxtecan (12mg/kg) vs CT (amrubicin, lurbinectedin or topotecan) to treat relapsed SCLC patients (n=~460) in Asia, EU, Oceania, North & South America
- The dual 1EPs include ORR (evaluated by BICR) & OS while the 2EPs are ORR (evaluated by the investigator) as well as PFS, DoR, DCR & time to response (investigated by both BICR & investigator)
- The updated subgroup analysis from P-I/II (IDeate-PanTumor01) study (highlighted at the WCLC 2023) of ifinatamab deruxtecan formed the basis of this study
Ref: Merck | Image: Merck & Daiichi Sankyo
Related News:- Merck Reports the CHMP’s Positive Opinion of Keytruda Plus Padcev to Treat Unresectable or Metastatic Urothelial Carcinoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
